AbbVie
ABBV
#28
Rank
NZ$805.73 B
Marketcap
NZ$455.96
Share price
-0.34%
Change (1 day)
25.50%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2026 (TTM): NZ$3.51

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$3.58. In 2025 the company made an earnings per share (EPS) of NZ$4.16 a decrease over its 2024 EPS that were of NZ$4.21.

EPS history for AbbVie from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$3.51-15.61%
2025NZ$4.16-1.26%
2024NZ$4.21-11.86%
2023NZ$4.78-58.95%
2022NZ$11.642.49%
2021NZ$11.36121.58%
2020NZ$5.13-44.7%
2019NZ$9.2745.84%
2018NZ$6.369.72%
2017NZ$5.79-9.54%
2016NZ$6.4116.28%
2015NZ$5.51184.1%
2014NZ$1.94-57.15%
2013NZ$4.52

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.28-36.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$49.09 1,272.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$25.19 603.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$16.26 354.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$12.91 260.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.19 73.08%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$12.09 237.90%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$6.76 88.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$11.67 226.23%๐Ÿ‡บ๐Ÿ‡ธ USA